Pfizer, BioNTech and Moderna
Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...
Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor ...
Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...
Lehigh County Courthouse staffer Adam Young sits with his face shield on as a juror would during a video shoot at the ...
As sales of its COVID vaccine plummet, Novavax is looking ahead toward other novel vaccines, brought to market with the help ...
BioNTech (BNTX) expects its revenues for the full 2025 financial year to be in the range of EUR 1.7B-EUR 2.2B and revenue phasing similar to ...
Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...
2d
Investor's Business Daily on MSNWhy Moderna Stock Has Surged 20% This Week Despite Mixed NewsModerna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open ...
Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results